1. Scrip
  2. >>Business
  3. >>Deals

Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization

 
• By Jessica Merrill

The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.

paper rip
Eisai and Bristol ended an ADC collaboration • Source: Shutterstock

Eisai Co., Ltd.’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisai announced the end of the three-year partnership on FZEC, formerly known as MORAb-202, on 1 July and said it plans to accelerate development of the product and conduct development and commercialization independently.

Key Takeaways
  • Eisai plans to accelerate development of farletuzumab ecteribulin after regaining full rights from Bristol Myers Squibb.
  • Farletuzumab ecteribulin is a folate receptor alpha (FRα)-targeting ADC in...

Bristol paid handsomely for rights to co-develop and co-commercialize FZEC in regions including the US, Europe and Asia in 2021. (Also see "BMS, Eisai Team Up To Accelerate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

More from Business